|
1
|
Koskas M, Amant F, Mirza MR and Creutzberg
CL: Cancer of the corpus uteri: 2021 update. Int J Gynaecol Obstet.
155 (Suppl 1):S45–S60. 2021. View Article : Google Scholar
|
|
2
|
Concin N, Matias-Guiu X, Vergote I, Cibula
D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti
A, et al: ESGO/ESTRO/ESP guidelines for the management of patients
with endometrial carcinoma. Int J Gynecol Cancer. 31:12–39. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang Z, Yang X, Liu X, Ma K, Meng YT, Yin
HF, Wen J, Yang JH, Zhen Z, Feng ZH and Liao QP: Clinical
characteristics and prognostic characterization of endometrial
carcinoma: A comparative analysis of molecular typing protocols.
BMC Cancer. 23:2432023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang SZ, Zhang L and Xie L: Cancer Burden
in China during 1990–2019: Analysis of the global burden of
disease. Biomed Res Int. 2022:39180452022.PubMed/NCBI
|
|
5
|
Kovacevic N: Surgical treatment and
fertility perservation in endometrial cancer. Radiol Oncol.
55:144–149. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van den Heerik ASVM, Horeweg N, de Boer
SM, Bosse T and Creutzberg CL: Adjuvant therapy for endometrial
cancer in the era of molecular classification: Radiotherapy,
chemoradiation and novel targets for therapy. Int J Gynecol Cancer.
31:594–604. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tung HJ, Huang HJ and Lai CH: Adjuvant and
post-surgical treatment in endometrial cancer. Best Pract Res Clin
Obstet Gynaecol. 78:52–63. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Crosbie EJ, Kitson SJ, McAlpine JN,
Mukhopadhyay A, Powell ME and Singh N: Endometrial cancer. Lancet.
399:1412–1428. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee YC, Lheureux S and Oza AM: Treatment
strategies for endometrial cancer: Current practice and
perspective. Curr Opin Obstet Gynecol. 29:47–58. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kasius JC, Pijnenborg JMA, Lindemann K,
Forsse D, van Zwol J, Kristensen GB, Krakstad C, Werner HMJ and
Amant F: Risk stratification of endometrial cancer patients: FIGO
stage, biomarkers and molecular classification. Cancers (Basel).
13:58482021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McAlpine J, Leon-Castillo A and Bosse T:
The rise of a novel classification system for endometrial
carcinoma; integration of molecular subclasses. J Pathol.
244:538–549. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang N, Zhang J, Fan X and Ma J, He J,
Kang S, Cheng J and Ma J: Identification of risk factors for the
prognosis of Chinese patients with endometrial carcinoma. Medicine
(Baltimore). 100:e273052021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liang S and Zhang Y: Clinical pathological
characteristics and survival of high-grade endometrioid carcinoma.
J Obstet Gynaecol Res. 47:3644–3651. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Y, Wang J, Zhao A, Huang X and Zhang
X: HPV16 E6E7 up-regulates KIF2A expression by activating JNK/c-Jun
signal, is beneficial to migration and invasion of cervical cancer
cells. Open Med (Wars). 17:1780–1787. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu Y, Wang W, Chen J, Mao H, Liu Y, Gu S,
Liu Q, Xi Q and Shi W: High neuropilin and tolloid-like 1
expression associated with metastasis and poor survival in
epithelial ovarian cancer via regulation of actin cytoskeleton. J
Cell Mol Med. 24:9114–9124. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao P, Lan F, Zhang H, Zeng G and Liu D:
Down-regulation of KIF2A inhibits gastric cancer cell invasion via
suppressing MT1-MMP. Clin Exp Pharmacol Physiol. 45:1010–1018.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang K, Lin C, Wang C, Shao Q, Gao W, Song
B, Wang L, Song X, Qu X and Wei F: Silencing Kif2a induces
apoptosis in squamous cell carcinoma of the oral tongue through
inhibition of the PI3K/Akt signaling pathway. Mol Med Rep.
9:273–278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang D, Zhu H, Ye Q, Wang C and Xu Y:
Prognostic Value of KIF2A and HER2-Neu overexpression in patients
with epithelial ovarian cancer. Medicine (Baltimore). 95:e28032016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lei G, Xin X and Hu X: Clinical
significance of kinesin family member 2A as a facilitating
biomarker of disease surveillance and prognostication in cervical
cancer patients. Ir J Med Sci. 191:665–670. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tian Y, Zhao K, Yuan L, Li J, Feng S, Feng
Y, Fang Z, Li H and Deng R: EIF3B correlates with advanced disease
stages and poor prognosis, and it promotes proliferation and
inhibits apoptosis in non-small cell lung cancer. Cancer Biomark.
23:291–300. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wei DC, Yeh YC, Hung JJ, Chou TY, Wu YC,
Lu PJ, Cheng HC, Hsu YL, Kuo YL, Chen KY, et al: Overexpression of
T-LAK cell-originated protein kinase predicts poor prognosis in
patients with stage I lung adenocarcinoma. Cancer Sci. 103:731–738.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Neven P, Van Calster B, Van den Bempt I,
Van Huffel S, Van Belle V, Hendrickx W, Decock J, Wildiers H,
Paridaens R, Amant F, et al: Age interacts with the expression of
steroid and HER-2 receptors in operable invasive breast cancer.
Breast Cancer Res Treat. 110:153–159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Amant F, Mirza MR, Koskas M and Creutzberg
CL: Cancer of the corpus uteri. Int J Gynaecol Obstet. 143 (Suppl
2):S37–S50. 2018. View Article : Google Scholar
|
|
24
|
Yang H and Liu Y: Kinesin family member 2A
serves as a potential biomarker reflecting more frequent lymph node
metastasis and tumor recurrence risk in basal-like breast cancer
patients. Front Surg. 9:8892942022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sheng N, Xu YZ, Xi QH, Jiang HY, Wang CY,
Zhang Y and Ye Q: Overexpression of KIF2A is Suppressed by miR-206
and associated with poor prognosis in ovarian cancer. Cell Physiol
Biochem. 50:810–822. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang ZX, Ren SC, Chang ZS and Ren J:
Identification of kinesin family member 2A (KIF2A) as a promising
therapeutic target for osteosarcoma. Biomed Res Int.
2020:71027572020.PubMed/NCBI
|
|
27
|
Wang C, Xie X, Li W and Jiang D:
Expression of KIF2A, NDC80, CDK1, and CCNB1 in breast cancer
patients: Their interaction and linkage with tumor features and
prognosis. J Clin Lab Anal. 36:e246472022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bai F, He Z, Zhou H and Gan W: Kinesin
family member 2A links with advanced tumor stage, reduced
chemosensitivity and worse prognosis in gastric cancer. J Clin Lab
Anal. 36:e243132022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zaganjor E, Osborne JK, Weil LM,
Diaz-Martinez LA, Gonzales JX, Singel SM, Larsen JE, Girard L,
Minna JD and Cobb MH: Ras regulates kinesin 13 family members to
control cell migration pathways in transformed human bronchial
epithelial cells. Oncogene. 33:5457–5466. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schimizzi GV, Currie JD and Rogers SL:
Expression levels of a kinesin-13 microtubule depolymerase
modulates the effectiveness of anti-microtubule agents. PLoS One.
5:e113812010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu L, Zhang X, Wang Z, Zhao X, Zhao L and
Hu Y: Kinesin family member 2A promotes cancer cell viability,
mobility, stemness, and chemoresistance to cisplatin by activating
the PI3K/AKT/VEGF signaling pathway in non-small cell lung cancer.
Am J Transl Res. 13:2060–2076. 2021.PubMed/NCBI
|
|
32
|
Gou R, Zheng M, Hu Y, Gao L, Wang S, Liu
O, Li X, Zhu L, Liu J and Lin B: Identification and clinical
validation of NUSAP1 as a novel prognostic biomarker in ovarian
cancer. BMC Cancer. 22:6902022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chang H, Wang J, Tian Y, Xu J, Gou X and
Cheng J: The TPX2 gene is a promising diagnostic and therapeutic
target for cervical cancer. Oncol Rep. 27:1353–1359.
2012.PubMed/NCBI
|
|
34
|
Liu W, Xu C, Meng Q and Kang P: The
clinical value of kinesin superfamily protein 2A in hepatocellular
carcinoma. Clin Res Hepatol Gastroenterol. 45:1015272021.
View Article : Google Scholar : PubMed/NCBI
|
